GENERAL
Aurobindo Pharma Bets On Specialty Drugs, Biosimilars For Next Expansion
Aurobindo Pharma Ltd is doubling down on high-value specialty medicines, biosimilars and complex formulations while strengthening its manufacturing footprint and supply chain resilience as it charts its next phase of global growth. In his message to shareholders in the company’s Annual Report 2026, Vice Chairman & Managing Director K. Nithyananda Reddy said the company will […]
CW Bureau
·
Aug 4, 2026
GENERAL
Lupin Banks On Biosimilars, Specialty Medicines To Power Next Expansion
Lupin Ltd is stepping up its focus on biosimilars, specialty medicines, complex generics and artificial intelligence (AI) as it builds the next phase of its growth strategy, according to Chief Executive Officer Vinita Gupta and Managing Director Nilesh Gupta in a joint message to shareholders in the company’s Annual Report 2026. The leadership said years […]
CW Bureau
·
Jul 14, 2026
GENERAL
Aurobindo Pharma USA Gets USFTC Nod For $250-Mn Lannett acquisition
Aurobindo Pharma USA, Inc, a wholly owned subsidiary of Aurobindo Pharma Ltd, has received approval from the US Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC. The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end […]
CW Bureau
·
Jun 22, 2026
